Anita Shrestha

Anita Shrestha

Auto-generated profile, based on publicly available information

Anita Shrestha

Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Appetite
Verified
Journal Article
Open access
ASAnita Shrestha
Anita Shrestha
KCKatherine Cullerton
Katherine Cullerton
KWKatherine M. White
Katherine M. White
JMJenni Mays
Jenni Mays
MSMargo Sendall
Margo Sendall
An unhealthy diet is a leading contributor to the increasing burden of overweight and obesity. Front-of-pack labelling (FOPL) is being recognized as a policy strategy to promote healthier choices yet there is limited evaluation of FOPL to suggest if it is effective for all population subgroups. This systematic review aimed to assess the impact of FOPL on consumer understanding and usage across socio-economic gradients. Six electronic databases were searched through a systematic search process using key terms for FOPL and socioeconomic status (SES) from 2011 to March 2022 to include studies evaluating the effectiveness of FOPL. A narrative synthesis was conducted and the results were assessed according to the effects of FOPL on consumer awareness, understanding, and usage across SES. The review included 36 articles. In general, people of all SES groups were aware of and more likely to pay attention towards FOPL than the nutrition information panel provided on the back of the package. However, the understanding and usage were relatively poor, particularly in low SES groups. While studies conducted in low SES populations suggest FOPL increased the purchase intention of healthy products, the stratified analysis across SES showed less beneficial effects in low SES individuals. The findings highlight simplified and easy-to-understand FOPLs such as Nutri-score and traffic light labelling are likely to be effective for all populations including low SES groups. Overall, the review suggests FOPLs are more visible than the nutrition information panel and may guide healthier food choices for people of all SES backgrounds. It is unclear whether FOPL influences actual purchasing and food intake as there are insufficient studies comparing the effects among higher and lower SES populations.

21 January 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
SSSangita Shakya
Sangita Shakya
ASAnita Shrestha
Anita Shrestha
SRSuzanne Robinson
Suzanne Robinson
SRSean Randall
Sean Randall
GMGeorge Mnatzaganian
George Mnatzaganian
LGLan Gao
Lan Gao
Objectives: Coronary heart disease (CHD) is the leading cause of global morbidity and mortality, yet no comprehensive evaluation of its global economic costs exists. We conducted a systematic review with meta-analysis to examine the costs of CHD treatment by region and CHD subtypes, examine whether there are cost difference by sex, and examine costing methodologies. Design: We conducted a systematic review and meta-analysis of non-randomised studies. Data sources: We searched Medline, Embase, CINAHL, EconLit and Google Scholar from 1 January 2000 to February 2023. Eligibility criteria for selecting studies: We included observational studies reporting economic costs of CHD treatment and outcomes for adults that were published in English. Data extraction and synthesis: Data extraction and quality assessment were independently undertaken by two reviewers. Costs were converted to percentage of gross domestic product (GDP) per capita of corresponding country. A random-effects model was used for meta-analysis using StataSE V.18 to calculate the pooled percentage. Heterogeneity was assessed using the I 2 statistic. Meta-regression and bias assessment were performed. Results: Out of 20 100 records identified, 37 studies (including 2 564 189 individuals) from 22 countries were included in the qualitative synthesis and the quantitative meta-analysis. In most countries, the annual cost of CHD exceeds many times the total health expenditure per capita. The pooled direct annual cost of CHD per patient varied from 4.9% to 137.8% of GDP per capita (Int$ purchasing power parity), with pooled percentage of 21.7% (95% CI 15.3, 28.1) for those with CHD. Slight difference in the annual pooled cost of CHD was observed, with a 2% of GDP per capita higher cost in men (95% CI 0.8, 3.2). Most studies applied a top-down costing approach (n=21). Conclusions: The review illustrates the expense associated with CHD, which is varied by region and CHD subtypes. The observed cost difference by sex warrants further exploration of sex-specific factors influencing cost disparities. Exploring advanced costing methods such as time-driven activity-based costing can optimise resource allocation and identify opportunities to reduce unnecessary costs and cost disparities. PROSPERO registration number: CRD42023412044.